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Abstract
Background: The transient receptor potential (TRP) channel subtype A1 (TRPA1) is known to be expressed on
sensory neurons and respond to changes in temperature, pH and local application of certain noxious chemicals
such as allyl isothiocyanate (AITC). Artemin is a neuronal survival and differentiation factor and belongs to the glial
cell line-derived neurotrophic factor (GDNF) family. Both TRPA1 and artemin have been reported to be involved in
pathological pain initiation and maintenance. In the present study, using whole-cell patch clamp recording
technique, in situ hybridization and behavioral analyses, we examined the functional interaction between TRPA1
and artemin.
Results: We found that 85.8 ± 1.9% of TRPA1-expressing neurons also expressed GDNF family receptor alpha 3
(GFR a3), and 87.5 ± 4.1% of GFRa3-expressing neurons were TRPA1-positive. In whole-cell patch clamp analysis, a
short-term treatment of 100 ng/ml artemin significantly suppressed the AITC-induced TRPA1 currents. A
concentration-response curve of AITC resulting from the effect of artemin showed that this inhibition did not
change EC50 but did lower the AITC-induced maximum response. In addition, pre-treatment of artemin significantly
suppressed the number of paw lifts induced by intraplantar injection of AITC, as well as the formalin-induced pain
behaviors.
Conclusions: These findings that a short-term application of artemin inhibits the TRPA1 channel’s activity and the
sequential pain behaviors suggest a role of artemin in regulation of sensory neurons.
Background
Artemin belongs to glial cell line-derived neurotrophic
factor (GDNF) family that regulates the development
and the function of the nervous system. Artemin binds
to the GFR a3/RET receptor complex and then activates
several intracellular signaling pathways [1]. Artemin sup-
ports survival of sensory neurons in vitro and in vivo
apparently by interacting with GFRa3, which is highly
restricted in adult to neurons of the peripheral nervous
system (sensory and sympathetic). GFRa3i se x p r e s s e d
by a subpopulation of nociceptive sensory neurons,
some or all of which also express the Ret receptor tyro-
sine kinase, the transient receptor potential (TRP) ion
channel proteins TRPV1 and TRPA1 [2,3]. The expres-
sion of these channels in GFR a3-positive neurons sug-
gests that artemin signaling via GFR a3/Ret binding
could modulate neuron sensitivity.
TRPA1 is a member of branch A of the TRP family of
cation channels[4] and is expressed by a subset of small-
sized DRG or trigeminal ganglia neurons in neonatal
rats, adult rats and mice [5-7]. TRPA1 has been
reported to be activated by various kinds of noxious
compounds through covalent modification of cysteines
[5,8-13]. TRPA1 is also activated by an endogenous
aldehyde, 4-hydroxynonenal, bradykinin, intracellular pH
and CO2 [8,14-16]. Studies using knockout mice
demonstrated that TRPA1 is an important component
of the transduction machinery through which environ-
mental irritants and endogenous proalgesic agents depo-
larize nociceptors to elicit inflammatory pain [17,18]. A
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of formalin-induced pain behaviors by pharmacological
blockade or genetic ablation indicated that TRPA1 is
crucial in inflammatory pain [19]. Taking the above into
account, it is clear that this channel is importantly
involved in pain transmission in the primary afferents
and a potential target for analgesic development.
Recent reports suggested that artemin potentiates
TRPV1 signaling and induces behavioral hyperalgesia.
Overexpression of artemin increased the expression and
sensitivity of TRPV1 and TRPA1 in trigeminal afferents
signaling and induced behavioral hyperalgesia [20,21].
We have studied the modulation mechanism of TRPV1
and TRPA1 by inflammatory modulators and reported
that trypsin/tryptase-PAR2 signaling or bradykinin-B2R
signaling sensitizes TRPA1 channel through PLC and/or
PKA pathways to induce inflammatory pain [22-24]. In
the present study, we hypothesized that a functional
interaction of artemin and TRPA1 might contribute to
the pathogenesis of inflammatory pain. We observed
high co-expression of the TRPA1 with the GFR a3
receptor and found a significant enhancement of desen-
sitization of TRPA1 activity induced by artemin in rat
DRG neurons, which was also confirmed at the beha-
vioral level.
Methods
Immunohistochemistry
A l la n i m a le x p e r i m e n t a lp rocedures were approved by
the Hyogo University of Health Sciences Committee on
Animal Research (#2008-05, #2008-10) and were per-
formed in accordance with the National Institutes of
Health guidelines on animal care. Adult male Sprague-
Dawley (SD) rats (220-250 g; Japan Animals, Osaka,
Japan) were perfused transcardially with 1% paraformal-
dehyde in 0.1 M phosphate buffer followed by 4% paraf-
ormaldehyde in 0.1 M phosphate buffer (PB, pH 7.4).
The L4-5 DRGs were removed and processed for
TRPA1 immunohistochemistry as described in our pre-
vious study [23]. For double immunofluorescence, tyra-
mide signal amplification (TSA; NEN) fluorescence
procedures were used for TRPA1 (1:10,000) staining.
The raised rabbit primary antibody for TRPA1 [23] and
biotin conjugated Griffonia simplicifolia Isolectin B4
(IB4, Sigma, St. Louis, MO) at 1:1000 combined with
Alexa fluor 488 goat anti-rabbit IgG (1:500; Invitrogen/
Molecular Probes, Inc., Carlsbad, CA) and strept-avidin
conjugated with Alexa fluor 594 (1:500: Invitrogen/
Molecular Probes), respectively, were used for double
immunofluorescence staining [22].
In situ hybridization histochemistry (ISHH)
Adult male SD rats weighing 200-250 g were killed by
decapitation under deep ether anesthesia. The bilateral
L4, L5 DRGs were dissected out, rapidly frozen in pow-
dered dry ice, and cut on a cryostat at a 5 μm thickness.
Sections were thaw mounted onto MAS-coated glass
slides (Matsunami, Osaka, Japan) and fixed in 4% for-
maldehyde in 0.1 M PB (pH 7.4) for 20 min. After
washing with PB, the sections were treated with 10 μg/
ml protease K in 50 mM Tris/5 mM EDTA (pH 8.0) for
3 min at room temperature, postfixed in the same fixa-
tive, acetylated with acetic anhydride in 0.1 M triethano-
lamine, rinsed with PB, and dehydrated through an
ascending ethanol series. For dual ISHH of TRPA1 and
GDNF family receptors, we used a DIG-labeled probe
for TRPA1 (GenBank accession number AY496961,
nucleotides 302 - 769) and a
35S-labeled RNA probe for
Ret (GenBank accession number U22513, nucleotides
13-319), GFR a1 (GenBank accession number U97142,
nucleotides 652 - 955), or GFR a2 (GenBank accession
number U97143, nucleotides 362 - 702), or GFR a3
(GenBank accession number AF184920, nucleotides 164
- 604) in the same sections, respectively. The details of
the dual ISHH procedure have been described in our
previous study [6].
Mammalian cell culture
For primary culture of DRG neurons, DRGs were col-
lected from the adult SD rats (100-200 g) using sterile
techniques, and placed in ice-cold Earle’s balanced
salt solution (EBSS, Sigma). Adhering fat and connec-
tive tissue were removed and each DRG was placed
immediately in a medium consisting of 2 ml of EBSS
and 1.25 mg/ml of collagenase P (Sigma) and kept at
37°C for 60 min with occasional agitation. After disso-
ciation of the DRG cells, this cell suspension was cen-
trifuged for 5 min at 1000 rpm and the cell pellet was
re-suspended in EBSS supplemented with 10% fetal
bovine serum (FBS), 2 mM glutamax, penicillin, strep-
tomycin and vitamin solution. Recombinant rat nerve
growth factor (100 ng/ml, Sigma) was added to the
medium.
Electrophysiology
Whole-cell patch-clamp recordings were carried out at
1 day after dissociation of the DRG neurons. Voltage-
clamp experiments were performed at -60 mV holding
potential, and recordings were sampled at 5 kHz and
filtered at 2 kHz. Current densities (pA/pF) and nor-
malized currents (the third currents were normalized
t ot h es e c o n dc u r r e n t se v o k e db ya na g o n i s t )w e r e
measured. The current magnitude was quantified by
peak current amplitude in all experiments. A normal-
ized current was obtained by normalizing the third
application-induced current to the second one, and
just in case the magnitude of the second current by
agonist was larger than a half of the first current to
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tion by the first current. In experiments with DRG
n e u r o n s ,a f t e rA I T C( 3 0 0μM) application, capsaicin
(10 μM) was applied at the end of recording to identify
whether the AITC-induced current was mediated by
TRPA1 channels. Data were obtained just in case the
DRG neuron was sensitive to both AITC and capsaicin
application, since an AITC-activated current in capsai-
c i n - s e n s i t i v eD R Gn e u r o n si sc e r t a i n l yaT R P A 1 -
mediated event [18]. The standard bath solution con-
tained 140 mM NaCl, 5 mM KCl, 2 mM MgCl2,2m M
CaCl2, 10 mM HEPES and 10 mM glucose, pH 7.4
(adjusted with NaOH). In some experiments, artemin
(100 ng/ml) was included in the bath solutions. The
pipette solution contained 140 mM KCl, 2 mM MgCl2,
0.5 mM CaCl2,5m MM g A T P ,5m ME G T Aa n d5
mM HEPES, pH 7.2 (adjusted with Tris-base). The
concentration-response curves for the effect of artemin
on AITC-induced current densities (pA/pF) were fit by
the Hill equation using Origin 8.1 (OriginLab Corpora-
tion, Northampton, MA, USA). All patch-clamp
experiments were performed at room temperature
(~25°C; RT). The solutions containing drugs were
applied to the chamber (180 μl) by a gravity system at
af l o wr a t eo f4 - 7m l / m i n .
Behavioral studies
Sixteen and 10 male adult SD rats (200-250 g) were
used for the AITC-induced nocifensive behavioral ana-
lyses and formalin test, respectively. After adaptation, 50
μl artemin (10 μg/ml, in PBS) or PBS was injected intra-
plantarly into the rat left hind paw. Five minutes after
these injections, rats received intradermal injection of 50
μl of AITC (3% in liquid paraffin, Wako Pure Chemical
Industries, Ltd., Osaka, Japan) or formalin (3% in saline)
to the same area of artemin-injected plantar surface.
The rats were placed in a wire mesh cage immediately
after the injection. The numbers of hind paw lifts and
durations of flinches per 5 min interval during the initial
30 min post-injection of AITC and 60 min post-infec-
tion of formalin period were measured for the AITC-
induced nocifensive behavior and formalin test, respec-
tively. The total number of lifts and durations of flinches
during the entire initial 30 min for AITC and 60 min
for formalin post-injection were also calculated.
Statistical analysis
All results are expressed as mean ± SEM. An unpaired
t-test or ANOVA followed by Fisher’s PLSD was used
to compare the calcium imaging data and electrophysio-
logical data between the groups. Two-way repeated
ANOVA followed by Fisher’s PLSD was applied to the
behavioral data. A difference was accepted as significant
if the probability was less than 5% (p < 0.05).
Results
Colocalization of TRPA1 with GDNF family receptors in rat
DRG neurons
Nociceptors can be neurochemically classified into two
subpopulations and modulated by neurotrophic factors
differently in each population. Double immunofluores-
cent staining indicated that 82.2 ± 1.1% of TRPA1 posi-
tive neurons were also labeled with IB4, a marker of the
nonpeptidergic and GDNF family members-dependent
neurons, and 44.1 ± 1.9% of IB4-positive neurons were
also stained for TRPA1 (Figure 1A). To further deter-
mine the histological evidence of colocalization with
TRPA1 and GDNF family receptors, we examined the
co-localization of TRPA1 mRNAs with Ret, GFR a1,
GFR a2, and GFR a3 mRNAs using double ISHH (Fig-
ure 1B-E). We observed these mRNAs were expressed
in 36.9 ± 2.6% (TRPA1), 77.4 ± 3.2% (Ret), 45.6 ± 4.9%
(GFR a1), 44.1 ± 1.7% (GFR a2) and 38.4 ± 2.7% (GFR
a3) of the total neuronal profiles. A significant popula-
tion of TRPA1-positive neurons were also labeled for c-
Ret and GFR a3( a r r o w si nF i g u r e1 B ,E )i nt h eD R G
(Table 1). The high percentages of colocalization; 99.3 ±
0.6% and 85.8 ± 1.9% of TRPA1 expressing neurons
were Ret- and GFR a3-positive, respectively, suggest
that TRPA1 is selectively expressed by artemin-sensitive
Ret/GFR a3 neurons (Figure 1B and 1E). In contrast to
the high incidence of co-localization of TRPA1 and GFR
a3, only 13.5 ± 7.7% and 45.9 ± 7.6% of TRPA1-positive
neurons were also labeled for GFR a1a n dG F Ra2,
respectively (Figure 1C and 1D). This high percentage of
co-expression of TRPA1 with GFR a3i nD R Gn e u r o n s
indicates a possible interaction between them in primary
afferent neurons.
Artemin suppresses AITC-induced current in DRG neurons
Based on the histological results, we hypothesized that
artemin may play important roles in the functional
modulation of TRPA1. To this end, we performed
whole-cell voltage-clamp experiments in cultured rat
DRG neurons. We found that application of artemin
alone to cause no change of membrane currents in cul-
tured DRG neurons. AITC, as a selective activator of
TRPA1, had been used in patch-clamp experiment to
detect the TRPA1 current. A previous study indicates
that there are still AITC-sensitive cells in TRPA1 knock-
out mice, but these are not the TRPV1-expressing cells
where most TRPA1 is expressed [18]. To confirm the
AITC-evoked current in DRG is a TRPA1-mediated
event, capsaicin at 10 μM was applied at the end of
recording using the patch-clamp preparation (see Mate-
rials and Methods section).
We observed that the AITC-activated inward currents
in DRG neurons underwent a weak tachphylaxis, giving
a smaller response on repeated applications of 300 μM
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demonstrated that G protein-coupled receptor signals
can potentiate the TRPA1 activity [23,24]. However, in
the present study, instead of potentiation, after 2 min
pretreatment with artemin (100 ng/ml), reapplication
of AITC with the same dose produced much smaller
current responses than the preceding application of
AITC. The normalized currents were significantly
smaller in the artemin-pretreated group than that in
the control group, which was not pretreated with arte-
min (0.9 ± 0.09-fold change, n = 11 for control; 0.3 ±
0.09-fold change, n = 6 for artemin; p < 0.005). A
smaller effect was detected in cells pretreated with
artemin in low concentrations (1 ng/ml) (0.8 ± 0.05-
fold change, n = 4 for 1 ng/ml p > 0.05 versus control)
(Figure 2B and 2C). This suppression effect lasted at
least 8 min after artemin application (Figure 2D). To
further confirm the inhibitory effect of TRPA1 by arte-
min, we also tested the effect of artemin on AITC-
induced current density in DRG neurons. After 2 min
pretreatment of artemin, the current density induced
by AITC (300 μM, 1 min) was significantly suppressed
(-30.8 ± 8.74 pA/pF, n = 8 for control, -9.5 ± 4.25 pA/
pF, n = 8 for artemin, p < 0.05 vs control) (Figure 3A-
C). To examine how artemin changes TRPA1 respon-
siveness, we measured AITC-induced current density
by applying a range of concentrations of AITC in the
a b s e n c eo rp r e s e n c eo fa r t e m i n .W ef o u n dt h a tt r e a t -
ment of artemin suppressed the maximum response
(-64.4 ± 13.36 pA/pF for control vs -19.8 ± 11.16 pA/
pF for artemin) without conspicuously affecting EC50
(343 μM for control vs 396 μM for artemin) (Figure
3D). These data clearly indicate a suppressive effect of
artemin on TRPA1 channel activity.
Figure 1 Colocalization of TRPA1 and IB4, Ret or GFR as in DRG neurons. (A): Double immunostaining of TRPA1 (green) and IB4 (red)
showed almost all of TRPA1 were expressed in IB4-labeled neurons of the naïve rat DRG. (B-E): Colocalization of TRPA1 mRNA (brown cells) and
Ret (B), GFR a1 (C), GFR a2 (D), and GFR a3 (E) mRNAs (clusters of silver grains) using double ISHH with
35S-labeled antisense Ret and GFR as
probes combined with TRPA1 DIG-labeled probe. The bright field and dark field photographs are merged. Arrows indicate examples of double-
labeled neurons. Scale bar = 100 μmi nA ,=5 0μm in B-D.
Table 1 The percentage of DRG profiles that co-express
IB4, Ret, GFR a1, GFR a2, or GFR a3 and TRPA1 mRNA
(mean ± SE)
x x/total TRPA1/x x/TRPA1
TRPA1 36.9 ± 2.6% 100% 100%
IB4 N.A. 44.1 ± 1.9% 82.2 ± 1.1%
GFR a1 45.6 ± 4.9% 10.2 ± 5.1% 13.5 ± 7.7%
GFR a2 44.1 ± 1.7% 37.8 ± 7.0% 45.9 ± 7.6%
GFR a3 38.4 ± 2.7% 87.5 ± 4.1% 85.8 ± 1.9%
Ret 77.4 ± 3.2% 47.5 ± 5.5% 99.3 ± 0.6%
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Activation of TRPA1 by pungent natural products suggests
a nociceptive role for TRPA1. Both AITC and formalin has
been reported to cause nocifensive behaviors in animals
through TRPA1 activation [19,23]. To test whether artemin
treatment could suppress TRPA1-mediated pain behaviors,
we performed intraplantar injections with AITC or forma-
lin after pretreatment of artemin (10 μg/ml) and recorded
nocifensive behaviors of rats. Consistent with our previous
studies [23-25], both AITC- and formalin-injection
Figure 2 A short-term treatment of artemin decreased AITC-induced currents in DRG neurons. (A, B): Representative traces show TRPA1
currents produced by repeated AITC application without (A) or with (B) artemin (100 ng/ml) treatment. AITC was re-applied after artemin
administration for 2 min. (C): Bar graph shows the effect of artemin on AITC activated currents. Currents were normalized to the values evoked
initially by AITC application in the absence of artemin. Numbers in parenthesis indicate cells tested. (D): Representative traces show time-course
of TRPA1 currents induced by repeated AITC application after artemin (100 ng/ml) treatment. AITC (300 μM) in a bath solution was perfused for
20s in all experiments.
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injected hindpaw during the 30 or 60 min post-injection
period, whereas such behaviors were not observed in vehi-
cle-injected rats (data not shown). The injection of arte-
min did not cause any inflammatory reactions (e.g.
redness, swelling) and acute nocifensive behavior (e.g. paw
lifting, flinching or licking). Five min after pre-treatment
with the artemin, AITC or formalin was injected into the
same area of the hind paw. Pre-treatment with artemin
induced a significant decrease of the number of paw lifts
and the duration of paw flinches in the initial 30 min post-
injection period of AITC, compared to those of rats pre-
treated with vehicle (Figure 4). Administration of artemin
preceding the formalin injection also reduced the number
of flinches observed in both Phase I (0-5 min) and Phase
II (10-60 min) (Figure 5).
Figure 3 Suppression of AITC-induced current density in DRG neurons by artemin. (A, B): Representative traces show TRPA1 currents
produced by AITC application (300 μM, 1 min) in the absence (A) or presence (B) of artemin (100 ng/ml). AITC was applied for 1 min after
artemin administration for 2 min. (C): Bar graph shows the effect of artemin on AITC activated current density (pA/pF). Numbers in parenthesis
indicate cells tested. * p < 0.05 versus control (absence of artemin), unpaired t-test. (D): Concentration-response curves for AITC-induced current
in the present or absence of artemin. Figure shows averaged data fitted with the Hill equation (see methods). EC50 = 343 μM and Maximum
current density = -64.4 pA/pF in the absence of artemin, EC50 = 396 μM and Maximum current density = -19.8 pA/pF in the presence of
artemin. Data for each point were generated from separate neurons by application of AITC for 1 min after pretreatment of artemin or vehicle.
Holding potential (Vh) = -60 mV in all experiments.
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In recent years, the role of artemin, a GDNF family
member, in mediating neuropathic and inflammatory
pain has been received much attention. Artemin is
known to be one of the survival factors for sensory and
sympathetic neurons in vitro and in vivo. The long-term
intrathecal or systemic administration of artemin pre-
vented many of the nerve injury-induced changes in the
histochemistry of nociceptor neurons, and produced
dose- and time-related reversal of nerve injury-induced
pain behaviors [26-28]. On the other hand, overexpres-
sion of artemin up-regulated expression of TRPV1 and
TRPA1 channels and subsequently led to an increase of
neuronal activity and hyperalgesia [2,20]. Acute applica-
tion of artemin induced a significant potentiation of
TRPV1 function and produced acute thermal hyperalge-
sia [21]. In the present study, in contrast to the poten-
tiation of TRPV1 function by artemin, we observed that
a short-term application of artemin significantly sup-
pressed TRPA1 channels activity and the TRPA1-
mediated pain behaviors.
Artemin binds to GFR a3/Ret to induce extracellular
signals [1]. We found TRPA1 was highly coexpressed
with GFR a3 and RET (Figure 1). This finding is consis-
tent with a previous report that indicates nearly all GFR
a3-positive neurons express TRPV1 immunoreactivity,
and most of these neurons are also TRPA1 positive [2].
The high co-localization of TRPA1 and GFR a3p r o -
vides a possible histological prerequisite of the func-
tional interaction between these two molecules.
Figure 4 Artemin suppressed nocifensive behaviors induced by AITC intraplantar injection. Artemin (10 μg/ml) or PBS was pre-treated
subcutaneously 5 min before AITC (3% in 50 μl liquid paraffin) injection. (A-D): Left panels show the time course of the number of hind paw
liftings (A) and the duration of paw flinches (C) after AITC injection with artemin (ARTN) or PBS pre-treatment. The number counted per 5 min
interval in the initial 30 min post-injection period. Right panels show cumulative number of paw lifts (B) and cumulative duration of flinches (D)
over the first 30 min period after injection of AITC. * p < 0.05; versus PBS + AITC at each time point (unpaired t-test), # p < 0.05; ## p < 0.001;
versus PBS + AITC group (two-way repeated ANOVA followed by Fisher’s PLSD), $ p < 0.05; $$ p < 0.01; versus PBS + AITC group (two-way
factorial ANOVA). Numbers in parentheses indicate number of rats used in each group.
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application of artemin significant reduced the AITC-
induced TRPA1 current. This inhibitory regulation was
examined in two ways. First, artemin was delivered
between two applications of AITC and then the normal-
ized current (the next AITC-current versus the first
one) was collected (Figure 2). This approach allowed us
to confirm that the tested neuron was indeed a TRPA1-
expressing one, but tachyphylaxis of AITC-induced cur-
rent may have interrupted the analysis and made it diffi-
cult to explain the reduced normalized current solely as
an inhibition of TRPA1 channels, rather a cooperative
effect of an artemin-induced inhibition and the tachy-
phylaxis may have taken place. Therefore, we also per-
formed an experiment with sensory neurons pretreated
by artemin and then applied AITC to evaluate the cur-
rent density. Both of these results clearly indicated inhi-
bitions of TRPA1 channel function by acute application
of artemin.
Acute application of artemin has been reported to
induce potentiation of another TRP channel, TRPV1,
and produce acute thermal hyperalgesia [21], TRPV1
and TRPA1 are structurally endowed with the same
TRP domain but have distinctly different intracellular
loops. AITC activates TRPA1 by covalently modifying
cysteine residues located in the N terminus of the chan-
nel, different from a classical lock-and-key binding
mechanism for capsaicin-TRPV1. Thus it is not a won-
der that the regulatory mechanism of TRPV1 and
TRPA1 may differ. For example, PKC has been reported
to potentiate TRPV1 [22,29,30] but did not have any
effect on TRPA1[23,24]. On the other hand, Elitt et al
have reported that overexpression of artemin up-regu-
lated expression of TRPV1 and TRPA1 channels and
subsequently led to greater neuronal activity and hyper-
algesia [2,20]. These reports suggested a post-transcrip-
tional regulation of artemin (which might contribute as
a neurotrophic factor) on TRPV1 and TRPA1 channels,
are not discordant with our findings.
TRPA1 is known to be expressed on sensory neurons
and acted as an important component of pain. If arte-
min can suppress the TRPA1activation, pain sensation
that is caused through the TRPA1 channel may also be
suppressed by the artemin activation. Topical applica-
tion of AITC has been reported to excite sensory nerve
fibers, thereby producing acute pain [5,17,31]. Consis-
tent with our electrophysiological data, artemin pro-
duced a significantly persistent suppression of the
duration of paw flinch and the number of paw lifts
induced by intraplantar injection of AITC (Figure 3). A
recent study indicates that TRPA1 is the principal site
of formalin’s pain-producing action in rodents [19]. The
formalin test is a widely used model of continuous pain
resulting from formalin-induced tissue injury. Subcuta-
neous injection of formalin into the rat hindpaw pro-
duces a biphasic pain response that consists of an early,
acute phase (Phase I) and a late, tonic phase (Phase II)
that is manifested behaviorally as lifting, flinching or
licking of the affected paw, and these behaviors are
robust and readily quantifiable [32,33]. Phase I is
thought to result from direct activation of primary affer-
ent sensory neurons, whereas Phase II has been
Figure 5 Artemin suppressed nocifensive behaviors induced by formalin. Artemin (10 μg/ml) or PBS was pre-treated subcutaneously 5 min
before formalin (3% in 50 μl saline) injection. Time course (A) and cumulative data (B) of the number of hind paw flinches after formalin
injection with artemin or PBS pre-treatment were measured. The number counted per 5 min interval in the initial 1 h post-injection period in A.
B shows cumulative number of paw flinches during the Phase I (0-5 min) and the second Phase II (10-60 min) after injection of formalin. * p <
0.05; ** p < 0.01; *** p < 0.0005; **** p < 0.0001 versus PBS + formalin (unpaired t-test), # p < 0.001; versus PBS + formalin (two-way repeated
ANOVA followed by Fisher’s PLSD), $ p < 0.005; $$ p < 0.0001 versus PBS + formalin (two-way factorial ANOVA). Numbers in parentheses
indicate number of rats used in each group.
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and central sensitization in the dorsal horn. In our pre-
sent study, we found artemin treatment significantly
suppressed the formalin-induced pain behaviors at both
two phases (Figure 3). Direct inhibition of TRPA1 activ-
ity by local injection of artemin in the plantar nerve
terminal may result the suppression of behaviors in
Phases I, then the reduced input of primary afferent
may contribute the reduction of pain behaviors in Phase
II. These findings suggest that a short-term application
of artemin inhibits the TRPA1 channel’s activity and the
sequential pain behaviors.
The mechanism of artemin-induced inhibition of
TRPA1 activity is not clear. Two potential mechanisms
are suggested to be involved in this regulation. One
would be that artemin increases EC50 by suppressing
the binding affinity of AITC to TRPA1. The other
mechanism would be that artemin lowers the channel
density of TRPA1 on cell membranes through promot-
ing receptor internalization or by inhibiting membrane
insertion of TRPA1 channels. In the present study, the
concentration-response curves of AITC resulting from
the effect of artemin (Figure 3C) revealed that artemin
lowered the maximal response of AITC without con-
spicuously altering EC50, indicating that artemin may
suppress AITC response in DRG neurons principally by
lowering the channel density. Distinct constitutive and
regulated vesicular trafficking mechanisms have critical
roles not only in controlling the surface expression of
TRP channels but also their activation in response to
stimuli [34]. TRPA1 may cycle between the plasma
membrane and intracellular compartments, and the bal-
ance between membrane insertion and retrieval deter-
mines its surface abundance and activity [35]. A recent
report indicated that TRPA1 channel desensitization in
sensory neurons was regulated by internalization of itself
[36]. Artemin-induced GFR a3/RET activation results in
stimulation of multiple signal transduction pathways,
including the MAP kinase/Erk and PI3 kinase/Akt path-
ways. A potential mechanism of inhibition of TRPA1 by
artemin in the present study may be the internalization
of the channels, which is regulated by the downstream
of GFR a3/RET intracellular signals. On the other hand,
it has been reported that TRPA1 is functionally inacti-
vated in sensory neuron by extracellular Ca
2 influx [37].
Although activation of GFR a3/RET signals results in
intracellular Ca
2 mobilization, however, it is not a likely
mechanism for the AITC-evoked current decrease
observed in our experiment. The reason simply comes
from that cytosolic-free Ca
2 is tightly chelated with the
5 mM EGTA included in the pipette solution. Anyway,
detailed mechanisms of artemin regulation on TRPA1
need to be further studied.
Conclusions
Artemin is widely expressed in nervous system [38],
supports the survival and regulates the differentiation of
peripheral neurons, including sympathetic, parasympa-
thetic, sensory and enteric neurons [3,39-41]. We now
show the interaction of artemin and TRPA1 in the rat
nervous system and provide a novel role of artemin in
inhibitory regulation of sensory neurons in the current
study. Artemin may have certain functions in both the
neurotrophic effects and inhibitory actions on sensory
neurons.
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